Alpha-1 antitrypsin augmentation therapy has already been proven effective in reducing pDES in the subgroup of COPD patients with alpha-1 antitrypsin deficiency [24]. This evidence concerns the gene SERPINA1 and hyperinsulinemic hypoglycemia, familial, 4.